| Market Cap | 91.02M | P/E | - | EPS this Y | 20.20% | Ern Qtrly Grth | - |
| Income | -43.11M | Forward P/E | -1.42 | EPS next Y | 6.10% | 50D Avg Chg | 2.00% |
| Sales | 9.57M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 15.00% |
| Dividend | N/A | Price/Book | 0.84 | EPS next 5Y | - | 52W High Chg | -36.00% |
| Recommedations | 2.60 | Quick Ratio | 4.88 | Shares Outstanding | 41.30M | 52W Low Chg | 140.00% |
| Insider Own | 7.73% | ROA | -29.46% | Shares Float | 24.89M | Beta | 2.41 |
| Inst Own | 48.64% | ROE | -55.37% | Shares Shorted/Prior | 248.99K/205.43K | Price | 2.29 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 138,196 | Target Price | 2.50 |
| Oper. Margin | -623.35% | Earnings Date | Nov 11 | Volume | 75,018 | Change | 1.33% |
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.